Cytotoxic T lymphocyte

Abstract

The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.

1 . An RNA-introduced T lymphocyte into which an RNA encoding an antigen of interest is introduced, which has an activity to induce a T lymphocyte which recognizes the antigen.  
     
     
         2 . The RNA-introduced T lymphocyte according to  claim 1 , which is a CD4-positive cell activated with phytohemagglutinin.  
     
     
         3 . A method for inducing a T lymphocyte, comprising using, as an antigen-presenting cell, an RNA-introduced T lymphocyte into which an RNA encoding an antigen of interest is introduced, to induce a T lymphocyte which recognizes the antigen.  
     
     
         4 . The method according to  claim 3 , wherein the RNA-introduced T lymphocyte is a CD4-positive cell activated with phytohemagglutinin.  
     
     
         5 . The method according to  claim 3 , wherein the T lymphocyte which recognizes the antigen is a cytotoxic T lymphocyte positive to CD8.  
     
     
         6 . The method according to any one of  claims 3  to  5 , wherein the antigen is a tumor-associated antigen or an antigen of an infectious microorganism.  
     
     
         7 . The method according to  claim 6 , wherein the RNA is an RNA prepared from a cancer tissue.  
     
     
         8 . The method according to  claim 6 , wherein the antigen is EBNA3A and/or CMVpp65.  
     
     
         9 . An immune inducer containing the RNA-introduced T lymphocyte as defined in  claim 1  or  2 .  
     
     
         10 . A therapeutic agent for cancer or infectious disease, containing the T lymphocyte obtained by the method of any one of  claims 3  to  8  as an active ingredient.  
     
     
         11 . A cytotoxic T lymphocyte which recognizes a cell presenting on the surface thereof a complex of a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO: 1 or 2 and an HLA-A24 molecule or a complex of a functional derivative of the HLA-A24-restricted antigen peptide and an HLA-A24 molecule, and which is CD8-positive.  
     
     
         12 . A therapeutic agent for cancer, containing the cytotoxic T lymphocyte of  claim 11 .  
     
     
         13 . An inducer of the cytotoxic T lymphocyte of  claim 11 , containing at least one peptide selected from the group consisting of a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO: 1 or 2 and a functional derivative thereof as an active ingredient.  
     
     
         14 . A therapeutic agent for cancer, containing a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO: 1 or 2 and a functional derivative thereof as an active ingredient.  
     
     
         15 . A tetramer for detecting a T cell receptor possessed by the cytotoxic T lymphocyte of  claim 11 , comprising a human major histo-compatibility antigen (HLA)-A24-restricted antigen peptide represented by SEQ ID NO: 1 or 2 or a functional derivative thereof.